INCYTE CORP/ US45337C1027 /
- - | Chg. - | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
-USD | - | - Turnover: - |
-Bid Size: - | -Ask Size: - | 15.61 bill.USD | - | 30.34 |
GlobeNewswire
08-16
China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profi...
GlobeNewswire
08-06
MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results
GlobeNewswire
08-01
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire
07-30
MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboratio...
GlobeNewswire
06-25
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitini...
GlobeNewswire
05-09
MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim ...
GlobeNewswire
05-08
Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update
GlobeNewswire
04-02
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sin...
GlobeNewswire
04-01
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast ...
GlobeNewswire
02-28
Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Up...
GlobeNewswire
01-09
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030
GlobeNewswire
2023-12-09
CURE Media Group announces winners of the 2023 MPN Heroes® Recognition Program
GlobeNewswire
2023-11-16
CURE Media Group® announces Jane Fonda as keynote speaker for the 2023 MPN Heroes® recognition progr...
GlobeNewswire
2023-11-02
Merus Announces Financial Results for the Third Quarter 2023 and Provides Business Update